Home / Science / MOTS-c Identified as a Mitochondrial-Encoded Host Defense Peptide

mots-cmitochondrial-peptidesinnate-immunitynew-research

MOTS-c Identified as a Mitochondrial-Encoded Host Defense Peptide

August 21, 2026

Nearly all published work on MOTS-c sits in one research area: metabolism. The peptide is characterised as an AMPK-linked signal, studied for glucose handling and framed as an exercise-responsive molecule. A paper published in eLife on 18 August 2026 proposes a second, largely separate function. Rice, Imun, Jung and colleagues at the University of Southern California — the group led by Changhan Lee, who first described MOTS-c in 2015 — report that the peptide behaves as a host defense peptide, with direct antibacterial activity and the ability to reprogramme immune cells.

What a host defense peptide is

Host defense peptides, often called antimicrobial peptides, are short sequences that innate immune systems across essentially all branches of life use as a first line of response. Two features define the class chemically: a net positive charge and an amphipathic structure, meaning the molecule has distinct water-facing and lipid-facing faces. That combination lets them associate with and destabilise bacterial membranes, which carry more negative surface charge than host cell membranes. Many members of the class do a second job as well, shaping the behaviour of immune cells rather than only killing microbes outright.

Until now, every characterised host defense peptide in humans has been encoded in nuclear DNA. That is the assumption the new paper challenges.

What the study reports

The authors assemble several independent lines of evidence:

Peptide chemistry. MOTS-c is cationic and amphipathic, matching the structural profile of known host defense peptides rather than that of a classical signalling peptide.
Direct antibacterial activity. In culture, MOTS-c acted against Escherichia coli and methicillin-resistant Staphylococcus aureus (MRSA). The authors attribute this in part to membrane targeting driven by the peptide’s hydrophobic and cationic regions.
An in vivo infection model. In a mouse model of acute peritonitis, the paper reports that MOTS-c neutralised MRSA infectivity.
Inducible expression. In human monocytes, interferon gamma, lipopolysaccharide, and differentiation signals each raised endogenous MOTS-c expression. In other words, the peptide is upregulated by exactly the cues that switch on nuclear-encoded immune genes.
Immune cell programming. When applied during the differentiation of primary mouse monocytes, MOTS-c produced macrophages carrying transcriptional signatures tied to antigen presentation and interferon signalling. Those macrophages cleared bacteria more effectively and showed a shifted metabolic profile.

Why the mitochondrial origin matters

Mitochondria descend from a bacterial endosymbiont, and mitochondrial DNA retains a small set of protein-coding genes. Mitochondrial DNA was already known to participate in immunity, but as a trigger — released mtDNA acts as a danger signal, and it can physically entrap pathogens as part of extracellular trap structures. What it was not thought to do is encode a functional immune effector.

The paper’s broader claim follows from that: if MOTS-c is a genuine host defense peptide, then the human immune repertoire is not written entirely in the nuclear genome. The authors suggest the activity is inherited from the proto-mitochondrial bacterium itself, which would make it one of the older components of innate defense still in use.

What this changes for readers following the MOTS-c literature

Two practical implications stand out.

The first is that the MOTS-c literature is likely to fork. Anyone tracking this compound should expect a growing body of immunology and infection work sitting alongside the existing metabolic research, using different models and different endpoints.

The second concerns how circulating MOTS-c measurements are interpreted. A recurring study design measures MOTS-c levels in blood and correlates them with metabolic or exercise variables. If inflammatory signals such as interferon gamma and lipopolysaccharide raise MOTS-c expression, then immune activation becomes a plausible confounder in those correlations — worth keeping in mind when reading observational papers in this area.

Caveats

This is preclinical work. The evidence comes from bacterial cultures, a mouse peritonitis model, and cell-culture experiments on monocyte differentiation. There is no human clinical data here, and the findings describe the peptide’s biology in laboratory systems rather than establishing any application in people.

The eLife version of record updates a preprint first posted to bioRxiv in 2023 and revised in 2024, so the core observations have been in circulation for some time ahead of peer-reviewed publication. The paper also carries a declared conflict of interest: the senior author is a consultant and shareholder in CohBar, Inc., a company built around mitochondrial-derived peptides. Neither point invalidates the work, but both are relevant context when weighing a first-in-class claim.